June 5, 2014 / 2:05 PM / 4 years ago

BRIEF-GSK starts phase III of coronary drug test

June 5 (Reuters) - GlaxoSmithKline Plc :

* GSK announces start of phase III cardiovascular outcomes study with Losmapimod in patients with acute coronary syndrome

* Phase III study will assess whether Losmapimod can reduce risk of a subsequent cardiac event when administered orally twice a day for a period of three months immediately after presentation with an acute coronary syndrome Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below